Navigation Links
FDA approves IND on Lead Product M6G

CAMBRIDGE, England, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV). The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review. Neil Clark, Chief Executive of CeNeS, said:

"The FDA's approval of our IND application for M6G is a major landmark in CeNeS' clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: '"/>




Page: 1 2

Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
4. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
5. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves IND Lead Product
(Date:11/6/2009)...Nov. 6 Derma Sciences,...advanced wound care products, announced plans to r...t on Monday, November 16, 2009. The Company will h... results at 11:00 am EST. Interested parties shoul... (international), with passcode 81416481 to access...
(Date:11/6/2009)... Nov. 6 Philips Respironics applau...and Prevention (CDC) to raise awareness about an i...fficiency. The CDC,s release of the first-ever gov...s in sleeplessness is a milestone in quantifying t...-time educator, industry leader and sleep therapy ...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq:...ort financial results for the second quarter ended...30, 2010 on Wednesday, November 18, 2009 at 5:00 P... to discuss those results on Thursday, November 19...cond Quarter Results Conference Call Instructions ...
Breaking Medicine Technology:Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Ulcerative colitis treatment reduces need for surgery by almost half 58614 1Ulcerative colitis treatment reduces need for surgery by almost half 58614 2Platelet rich plasma 3A Does it work 3F 58610 1Platelet rich plasma 3A Does it work 3F 58610 2Platelet rich plasma 3A Does it work 3F 58610 3Entomological Society of America names 2009 award winners 10202 1Entomological Society of America names 2009 award winners 10202 2
...16 DURECT Corporation (Nasdaq: DRRX ) announced...b clinical trial conducted by Endo Pharmaceuticals...ay patch under development for the treatment of ch...candidate was reviewed with the U.S. Food and Drug...hase II meeting with the FDA on February 19, 2009....
...nnocoll, Inc., a privately-held biopharmaceutical ...dosed in the first of two ongoing U.S. phase 3 cli...ary, Innocoll Technologies Ltd, to investigate Col...tion of surgical site infections. , , The trial i...es across the U.S. and has enrolled 1,500 diabetic...
Other Medicine Technology:DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 2DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 3DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 4DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 5Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 2Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 3
(Date:11/8/2009)...swire-USNewswire/ -- Pharmaceutical Research and M...ent Ken Johnson released the following statement r..."We are disappointed, but not surprised by today,s...orking Americans as well as nearly half of the mem...d against the bill. ,, "While well intentioned,...
(Date:11/8/2009)...ho Sides With Working Families vs. Insurance Compa...Newswire/ -- On the heels of an historic late nigh... balanced health care reform bill, the Pennsylvani...U.S. representatives voted on HR 3962, the Afforda...ation, which passed Saturday evening by a vote of ...
(Date:11/7/2009)...Newswire-USNewswire/ -- Speaker Nancy Pelosi spok..., the Affordable Health Care for America Act. The... Below are the Speaker,s remarks. ,, "Madam S...nt for our nation and for American families. For ...ical philosophy -- as far back as Teddy Roosevelt ...
(Date:11/7/2009)...re/ -- Calling this a "defining moment" for the Am...t J. James Rohack, M.D., today addressed medical s...edical specialty societies at the opening of the A...th system reform will top the agenda. ,, (Logo:...ALOGO ) ,, "Over the next 72 hours, this AMA ...
(Date:11/7/2009)...swire-USNewswire/ -- The U.S. bishops November 7 u...te for the Stupak-Ellsworth Amendment to the healt...aptur-Dahlkemper-Lipinski-Smith Amendment will kee... and conscience protections in the Affordable Heal..., The letter was signed by Cardinal Justin Riga...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...itive Proxy Materials, BEDFORD, Mass., Sept. 12 ... of state-of-the-art diagnostic and,digital imagin...nnounced,that its registration statement, includin...nce mailing,definitive proxy materials in connecti...
...A (Sept. 12, 2007) Most of us have never heard of...ive parents from conceiving. , Immune infertilit...includes better-known diseases like Multiple Scler...ery at the University of Virginia Health System ma...
... disease showed effect after brief exposure to die...thDay News) -- Here,s a good reason not to take ...e heart disease who were exposed, even briefly, to...ks and arrhythmias. , The levels of pollution simu...
... Ahead on Reconciling Separate Bills, Despite the,...inistration Roadblocks, WASHINGTON, Sept. 12 U.S...to work out differences between their,separate ver...w many additional children would be covered in eac...
...ernor Calls the Quilt a ,Beautiful Symbol, NEW YO...ribed by her daughter, Jean Bolds, as "a homemaker...Henderson-Bolds took care of her,family --- hangin...u at the front door and you couldn,t,wait to eat!"...
...courage Muslims to use discipline of Ramadan fast ...HINGTON, Sept. 12 A prominent national,Islamic ci...s representing,American Muslim physicians today en... lunar calendar during which,Muslims abstain from ...
Other Medicine News:Health News:Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation 2Health News:Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation 3Health News:Hologic Sets Special Meeting of Stockholders to Vote on Proposed Merger with Cytyc Corporation 4Health News:UVA researchers find important clue to immune infertility 2Health News:Jogging in Traffic Cuts Blood Flow to Heart 2Health News:Jogging in Traffic Cuts Blood Flow to Heart 3Health News:Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan 2Health News:Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan 3Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 2Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 3Health News:Muslim Groups Kick Off Ramadan With Anti-Smoking Initiative 2Health News:Muslim Groups Kick Off Ramadan With Anti-Smoking Initiative 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: